Medtronic Raises Fiscal 2027 Forecasts Amid Heart Device Boom

Medtronic has revised its fiscal 2027 financial forecasts upward, citing robust demand for its heart devices used in complex cardiovascular procedures. The medical technology giant now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from its previous projection of 6.75% to 7.25%.

CEO Geoff Martha expressed confidence in the company's performance across various business segments, highlighting the significant contributions from newer growth platforms. "What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms," Martha remarked during a post-earnings call.

Strategic Investments in Heart Devices

In a strategic move to bolster its heart device portfolio, Medtronic announced an $80 million investment in Pi-Cardia, a company specializing in heart-valve repair devices. The deal includes an option for Medtronic to purchase Pi-Cardia for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States.

Martha pointed out the low penetration of soft tissue robotic surgery in emerging markets, which stands at less than 1%. He noted that Cornerstone's Sentire device complements Medtronic's Hugo device, underscoring the company's focus on high-growth segments with large patient pools.

Cardiovascular Segment Drives Growth

Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by the company's pulsed field ablation portfolio, which saw an impressive 88% increase and is used to treat irregular heart rhythms.

Overall, the company reported an adjusted quarterly per-share profit of $1.45 on revenue of $9.76 billion, surpassing analysts' expectations of $1.39 per share on $9.55 billion in sales, according to LSEG data.

Medtronic's Chief Financial Officer Thierry Pieton noted that the company received tariff refunds that nearly covered the duties paid during the quarter. However, these refunds have not been factored into the company's future outlook.

As Medtronic continues to navigate the medtech landscape, it remains committed to prioritizing high-growth sectors that promise substantial market opportunities. The company's strategic investments and revised forecasts reflect its adaptability and forward-thinking approach amid evolving healthcare demands.